Progress in cancer vaccines enabled by nanotechnology.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Therapeutic cancer vaccines have historically faced challenges with low clinical efficacy.
• Recent progress in vaccine technologies, regimens, and trial designs shows promise.

Purpose of the Study:

• To review advances in therapeutic cancer vaccines.
• To highlight the role of nanotechnologies in improving vaccine delivery and targeting.
• To discuss progress in antigen discovery and vaccine engineering.

Main Methods:

• Review of recent scientific literature on cancer vaccine development.
• Focus on nanotechnologies like lipid nanoparticles and lipoplexes for mRNA delivery.
• Examination of improved adjuvants and targeting technologies for peptide vaccines.

Main Results:

• Early-stage trials demonstrate substantial benefits in recurrence-free and overall survival.
• Nanotechnologies are crucial for effective mRNA and peptide vaccine delivery.
• Progress in antigen discovery and nucleic acid vaccine engineering contributes to improved outcomes.

Conclusions:

• Therapeutic cancer vaccines are showing increased promise due to technological advancements.
• Nanotechnology plays a key role in enhancing vaccine efficacy and patient survival.
• Further research is needed to overcome challenges and maximize the potential of cancer vaccines.